Related Experiment Video
Updated: Mar 11, 2026
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
The effect of low dosage of procaine on lung cancer cell proliferation
1Department of Anesthesiology, The First Affiliated Hospital and College of Clinical Medicine of HENAN University of Science and Technology, Luoyang City, Henan, China. maxiaowumaxiaowu@126.com.
Objective:
Non-small cell lung cancer (NSCLC) is the most common type of human lung cancer leading cause of cancer death worldwide. However, first-line drugs such as gefitinib and erlotinib showed great drug resistance in the clinical.
Materials And Methods:
The cell proliferation was evaluated by MTT assay; gene expression was detected by qPCR assay. The protein expression was analyzed by Western blotting.
Results:
Our results showed that in mouse models of lung cancer by A549 or NCI-H1975 xenograft, the local anesthetic drug Procaine (PCA) with 50 mg/kg specifically attenuated tumors compared with the vehicle-treated group. In vitro, PCA suppressed both two human NSCLC cell lines A549 and NCI-H1975 proliferation in a lower dose (at nM grade). The cell proliferation marker PCNA was also downregulated after PCA treatment in vivo. Furthermore, low-dose of PCA could inhibit the mRNA expression of the key NSCLC target EGFR selectively in the A549 cells, however, it was not observed in another cell line NCI-H1975, implying a specific signaling by PCA in the cell type.
Conclusions:
Taken together, our data indicate that PCA treatment leads to suppression of tumor growth and proliferation in A549 and NCI-H1975, and there is an EGFR transcription pathway by PCA in A549 cells.
